The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Benefits of pembrolizumab in progressive radioactive iodine refractory thyroid cancer: Results of the AcSé Pembrolizumab Study from Unicancer.
 
Sophie Leboulleux
Consulting or Advisory Role - Bayer; Eisai
 
Yann Godbert
Honoraria - Bayer; Eisai Europe; Lilly
Travel, Accommodations, Expenses - Eisai Europe
 
Nicolas Penel
Research Funding - Bayer (Inst); Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Janssen-Cilag
Other Relationship - PharmaMar
 
Segolene Hescot
No Relationships to Disclose
 
Christelle De La Fouchardiere
Honoraria - Merck Serono; Merck Serono; Roche; Roche
Consulting or Advisory Role - Amgen; Amgen; Bayer; Bristol-Myers Squibb; Lilly; Pierre Fabre; Roche; SERVIER
Research Funding - Roche
Travel, Accommodations, Expenses - Amgen; Amgen; Bristol-Myers Squibb; Celgene; Roche; Roche; SERVIER
Other Relationship - Incyte; MSD Oncology
 
Marie Blonski
No Relationships to Disclose
 
Livia Lamartina
Honoraria - Eisai
Consulting or Advisory Role - EISAI BAYER
Research Funding - AstraZeneca; Bayer
 
Sophie Cousin
No Relationships to Disclose
 
Christine Do Cao
Speakers' Bureau - Eisai
Travel, Accommodations, Expenses - Ipsen
 
Julien Hadoux
No Relationships to Disclose
 
Clotilde Simon
No Relationships to Disclose
 
Natalie Hoog Labouret
Employment - Amgen (I)
 
Sylvie Chevret
No Relationships to Disclose
 
Christophe Massard
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Debiopharm Group; Faron Pharmaceuticals; Genentech/Roche; INNATE PHARMA; Ipsen; Janssen; Lilly; MSD; Novartis; ORION; Pfizer; PharmaMar; Sanofi; Taiho Pharmaceutical